

PRECISION OPTICS Corp INC  
Form 10-Q  
May 15, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**S** QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended March 31, 2012**

**or**

**£** TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 001-10647**

**PRECISION OPTICS CORPORATION, INC.**

(Exact name of registrant as specified in its charter)

Massachusetts  
(State or other jurisdiction of incorporation or organization)

04-2795294  
(I.R.S. Employer Identification No.)

**22 East Broadway, Gardner, Massachusetts 01440-3338**

(Address of principal executive offices) (Zip Code)

**(978) 630-1800**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of the issuer's common stock, par value \$0.01 per share, at May 9, 2012 was 1,251,339 shares.

**PRECISION OPTICS CORPORATION, INC.**

**Table of Contents**

	Page
<b>PART I — FINANCIAL INFORMATION</b>	
<b>Item 1. Financial Statements</b>	3
Consolidated Balance Sheets	3
Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2012 and 2011	4
Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2012 and 2011	5
Notes to Consolidated Financial Statements	6
<b>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</b>	11
<b>Item 3. Quantitative and Qualitative Disclosures About Market Risk</b>	15
<b>Item 4. Controls and Procedures</b>	15
<b>PART II — OTHER INFORMATION</b>	
<b>Item 1. Legal Proceedings</b>	17
<b>Item 1A. Risk Factors</b>	17
<b>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</b>	17
<b>Item 3. Defaults Upon Senior Securities</b>	17
<b>Item 4. Mine Safety Disclosures (Not applicable.)</b>	17
<b>Item 5. Other Information</b>	17
<b>Item 6. Exhibits</b>	18

**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.****PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS****(UNAUDITED)**

	<b>March 31,</b>	<b>June 30,</b>
	<b>2012</b>	<b>2011</b>
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and Cash Equivalents	\$436,219	\$19,556
Accounts Receivable, net	119,479	148,824
Inventories, net	698,350	666,285
Prepaid Expenses	38,419	37,664
Total Current Assets	1,292,467	872,329
<b>PROPERTY AND EQUIPMENT</b>		
Machinery and Equipment	2,355,968	2,355,968
Leasehold Improvements	553,596	553,596
Furniture and Fixtures	148,303	148,303
Vehicles	19,674	19,674
	3,077,541	3,077,541
Less: Accumulated Depreciation	(3,030,440 )	(3,015,315 )
Net Property and Equipment	47,101	62,226
<b>OTHER ASSETS</b>		
Patents, net	-	188,260
<b>TOTAL ASSETS</b>	<b>\$1,339,568</b>	<b>\$1,122,815</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>		
<b>CURRENT LIABILITIES</b>		
10% Senior Secured Convertible Notes	\$68,819	\$780,833
Accounts Payable	294,781	709,395
Customer Advances	22,619	36,292
Accrued Employee Compensation	189,988	711,015
Accrued Professional Services	24,760	54,000

Edgar Filing: PRECISION OPTICS Corp INC - Form 10-Q

Accrued Warranty Expense	25,000	25,000
Other Accrued Liabilities	-	912
Total Current Liabilities	625,967	2,317,447
STOCKHOLDERS' EQUITY (DEFICIT)		
Common Stock, \$0.01 par value -		
Authorized - 50,000,000 shares Issued and Outstanding - 1,245,339 shares at March 31, 2012 and 971,013 shares at June 30, 2011	12,453	9,710
Additional Paid-in Capital	38,983,092	38,259,029
Accumulated Deficit	(38,281,944)	(39,463,371)
Total Stockholders' Equity (Deficit)	713,601	(1,194,632 )
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>	<b>\$1,339,568</b>	<b>\$1,122,815</b>

*The accompanying notes are an integral part of these consolidated interim financial statements.*

**PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS****FOR THE THREE AND NINE MONTHS ENDED****MARCH 31, 2012 AND 2011****(UNAUDITED)**

	<b>Three Months</b>		<b>Nine Months</b>	
	<b>Ended March 31,</b>		<b>Ended March 31,</b>	
	<b>2012</b>	<b>2011</b>	<b>2012</b>	<b>2011</b>
Revenues	\$382,264	\$495,423	\$1,380,787	\$1,615,096
Cost of Goods Sold	371,941	361,017	1,119,850	1,035,663
Gross Profit	10,323	134,406	260,937	579,433
Research and Development Expenses, net	198,608	163,672	498,842	637,259
Selling, General and Administrative Expenses	309,913	264,493	837,987	724,923
Gain on Sale of Assets and Other	(7,308 )	(6,443 )	(9,457 )	(36,434 )
Total Operating Expenses	501,213	421,722	1,327,372	1,325,748
Operating Loss	(490,890 )	(287,316)	(1,066,435)	(746,315 )
Gain on Sale of Patents	-	-	2,276,286	-
Interest Income	1	4	534	206
Interest Expense	(1,250 )	(15,000 )	(28,958 )	(45,000 )
Net Income (Loss)	\$(492,139 )	\$(302,312)	\$1,181,427	\$(791,109 )
Income (Loss) Per Share:				
Basic	\$(0.40 )	\$(0.31 )	\$1.04	\$(0.79 )
Diluted	\$(0.40 )	\$(0.31 )	\$0.97	\$(0.79 )
Weighted Average Common Shares Outstanding:				
Basic	1,245,339	971,013	1,135,432	1,002,669
Diluted	1,245,339	971,013	1,243,527	1,002,669

*The accompanying notes are an integral part of these consolidated interim financial statements.*



**PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS****FOR THE NINE MONTHS ENDED****MARCH 31, 2012 AND 2011****(UNAUDITED)**

	Nine Months Ended March 31,	
	2012	2011
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net Income (Loss)	\$ 1,181,427	\$(791,109)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities -		
Depreciation and Amortization	18,225	43,961
Gain on Sale of Patents	(2,276,286)	-
Gain on Sale of Assets	(9,457 )	(32,883 )
Stock-based Compensation Expense and Consulting Expense	52,160	15,361
Non-cash Interest Expense	28,958	45,000
Changes in Operating Assets and Liabilities -		
Accounts Receivable, net	29,345	245,040
Inventories	(32,065 )	(37,158 )
Prepaid Expenses	(755 )	(16,058 )
Accounts Payable	(414,614 )	226,905
Customer Advances	(13,673 )	(65,076 )
Accrued Expenses	123,466	(26,835 )
Net Cash Used In Operating Activities	(1,313,269)	(392,852)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Net Proceeds from Sale of Patents	2,463,171	-
Proceeds from Sale of Assets	9,457	32,883
Additional Patent Costs	(1,724 )	(16,027 )
Net Cash Provided By Investing Activities	2,470,904	16,856
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Payment of principal and interest on 10% Senior Convertible Notes	(740,972 )	-
Purchase of treasury stock (47,398 shares)	-	(474 )
Net Cash Used In Financing Activities	(740,972 )	(474 )
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>416,663</b>	<b>(376,470)</b>
<b>CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</b>	<b>19,556</b>	<b>416,040</b>
<b>CASH AND CASH EQUIVALENTS, END OF PERIOD</b>	<b>\$436,219</b>	<b>\$39,570</b>



SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash Paid for Income Taxes	\$912	\$912
----------------------------	-------	-------

SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING  
ACTIVITIES:

Issuance of common stock to satisfy deferred compensation obligations (245,326 shares)	\$674,645	\$-
--	-----------	-----

*The accompanying notes are an integral part of these consolidated interim financial statements.*

**PRECISION OPTICS CORPORATION, INC.**

**NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Operations

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly-owned subsidiaries (the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the third quarter of the Company's fiscal year 2012. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company's consolidated financial statements for the year ended June 30, 2011 together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company's 2011 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 28, 2011.

Use of Estimates

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Income (Loss) Per Share

Edgar Filing: PRECISION OPTICS Corp INC - Form 10-Q

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income or net loss (adjusted by adding back interest expense on senior convertible notes) by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants and shares issuable upon conversion of senior convertible notes. For the three months ended March 31, 2012 and for the three and nine months ended March 31, 2011, the effect of such securities was antidilutive and not included in the diluted calculation because of the net loss generated in those periods.

The following is the calculation of income (loss) per share for the three and nine months ended March 31, 2012 and 2011:

	<b>Three Months</b>		<b>Nine Months</b>	
	<b>Ended March 31</b>		<b>Ended March 31</b>	
	2012	2011	2012	2011
Net Income (Loss) – Basic	\$(492,139 )	\$(302,312)	\$1,181,427	\$(791,109 )
Interest Expense on Senior Convertible Notes	-	-	28,958	-
Net Income (Loss) – Diluted	\$(492,139 )	\$(302,312)	\$1,210,385	\$(791,109 )
Basic Weighted Average Shares Outstanding	1,245,339	971,013	1,135,432	1,002,669
Potentially Dilutive Securities	-	-	108,095	-
Diluted Weighted Average Shares Outstanding	1,245,339	971,013	1,243,527	1,002,669
Income (Loss) Per Share				
Basic	\$(0.40 )	\$(0.31 )	\$1.04	\$(0.79 )
Diluted	\$(0.40 )	\$(0.31 )	\$0.97	\$(0.79 )

The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 811,000 and 1,112,000 for the three months ended March 31, 2012 and 2011, respectively, and approximately 620,000 and 1,112,000 for the nine months ended March 31, 2012 and 2011, respectively.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

2. INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out) or market and consist of the following:

	<b>March 31, 2012</b>	<b>June 30, 2011</b>
Raw Materials	\$ 261,080	\$ 271,608
Work-In-Progress	317,631	312,097
Finished Goods	119,639	82,580
Total Inventories	\$ 698,350	\$ 666,285

3. 10% SENIOR SECURED CONVERTIBLE NOTES

On June 25, 2008, the Company entered into a Purchase Agreement, as amended on December 11, 2008, with institutional and other accredited investors (the "Investors") pursuant to which it sold a total of \$600,000 of 10% Senior Secured Convertible Notes (the "Notes") that are convertible at the Investor's option into a total of 480,000 shares of the Company's common stock at a conversion rate of \$1.25. The Company also issued warrants to purchase a total of 316,800 shares of its common stock at an exercise price of \$1.75 per share (the "Warrants"). Interest accrues on the Notes at a rate of 10% per year and is payable in cash upon the earlier of conversion or maturity of the Notes. The original maturity of the Notes was June 25, 2010 and the Warrants expire on June 25, 2015, subject to extension. By mutual agreement with the Company, the Investors amended the Notes on several dates to extend the "Stated Maturity Date" of the Notes. The conversion price of the Notes and the exercise price of the Warrants may be adjusted

downward in the event the Company issues shares of common stock or securities convertible into common stock at a price lower than the conversion price of the Notes or exercise price of the Warrants at the time of issuance.

Pursuant to the Purchase Agreement, the Notes and Warrants were not convertible or exercisable until the Company implemented a 1 for 6 reverse stock split, which required the approval of its stockholders. On November 25, 2008, the Company entered into a Side Letter Agreement in which the Investors agreed to change the ratio of the reverse split from 1 for 6 to 1 for 25. On December 11, 2008, the Company effected a 1 for 25 reverse split of its common stock.

Pursuant to a Registration Rights Agreement entered into with the Investors on June 25, 2008, the Company agreed to file a registration statement with the Securities and Exchange Commission by the earlier of (i) two days following the effectiveness of the amendment to implement a reverse stock split, and (ii) December 15, 2008, to register the resale of the common stock issuable upon the conversion of the Notes and the exercise of the Warrants. The Company agreed to keep the registration statement effective until the earlier of (i) the date on which all the securities have been sold, and (ii) the date on which all the securities may be sold without restriction pursuant to Rule 144 of the Securities Act of 1933.

The Notes contain covenants binding on the Company and certain events of default, including but not limited, to:

the failure of the Company to make a scheduled payment;

the failure of the Company to make payments in excess of \$100,000 on any liability or obligation, or if there is an acceleration of the stated maturity of any liability or obligation in excess of \$100,000; or

the Company entering bankruptcy.

If an event of default occurs and is uncured within the allowable grace period, if any, the Investors may declare all amounts under the Notes immediately due and payable and may pursue any other available remedies.

On December 15, 2011, the Company repaid Special Situations Fund III QP, L.P. a principal repayment of \$275,000 and accrued interest of \$95,486, for a total payment of \$370,486. On December 15, 2011, the Company repaid Special Situations Private Equity Fund, L.P. a principal repayment of \$275,000 and accrued interest of \$95,486, for a total payment of \$370,486. The Notes held by Special Situations Fund III QP, L.P. and Special Situations Private Equity Fund, L.P. have been satisfied in full and the obligations thereunder have been terminated.

On March 31, 2012, the remaining Investor, Arnold Schumsky, further amended his remaining Note to extend the “Stated Maturity Date” of the principal to July 31, 2012 and to modify the Note such that all accrued and unpaid interest on the Note up to and including March 31, 2012 shall be due on or before April 13, 2012, on the condition that the Company issue to him a warrant for 5,000 shares of common stock with an exercise price of \$1.20 per share and a term of three years. On April 13, 2012, the Company repaid Mr. Schumsky a payment of the accrued interest of \$18,819, and such payment included all accrued and unpaid interest on the Note up to and including March 31, 2012. On May 8, 2012, the Company issued Mr. Schumsky the warrant according to the terms described in the amended Note.

The 10% Senior Secured Convertible Notes consist of the following:

	March 31, 2012	<b>June 30, 2011</b>
10% Senior Secured Convertible Notes issued on June 25, 2008, convertible into common stock at \$1.25 per share, bearing interest at 10% per annum. Outstanding principal and accrued interest are due at maturity, July 31, 2012	\$50,000	\$600,000
Accrued interest—10% coupon due on April 13, 2012	18,819	180,833
	<b>\$68,819</b>	<b>\$780,833</b>

#### 4. STOCK-BASED COMPENSATION

On February 9, 2012, the Company granted an aggregate of 51,000 options to purchase shares of common stock at an exercise price of \$0.55 per share to certain employees, and agreed to issue 6,000 unregistered shares of common stock to a consultant, or his designee, as consideration for consulting services provided to the Company. On March 2, 2012, the Company granted an aggregate of 207,800 options to purchase shares of common stock at an exercise price of \$1.20 per share to certain officers and directors of the Company.

Stock-based compensation costs recognized during the quarters ended March 31, 2012 and 2011 amounted to \$34,260 and \$8,176, respectively, and the costs were included in the accompanying consolidated statements of operations in: selling, general and administrative expenses (2012 - \$33,360; 2011 - \$5,000), and cost of goods sold (2012 - \$900; 2011 - \$3,176). Stock-based compensation costs recognized during the nine month periods ended March 31, 2012 and 2011 amounted to \$52,160 and \$15,361, respectively, and were included in the accompanying consolidated statements of operations in: selling, general and administrative expenses (2012 - \$45,860; 2011 - \$5,833), and cost of goods sold (2012 - \$6,300, 2011 - \$9,528). No compensation has been capitalized because such amounts would have been immaterial. No income tax provision was recorded in the third quarter or first nine months of fiscal years 2012 or 2011 because of the availability of loss carryforwards to offset any anticipated taxable income in fiscal year 2012 and fiscal year 2011.

The following tables summarize stock option activity during the first nine months of fiscal year 2012:

	Options Outstanding		
	Number of	Weighted Average	Weighted Average
	Shares	Exercise Price	Contractual Life
Outstanding at June 30, 2011	94,138	\$ 15.97	4.50 years
Grants	506,600	0.27-1.20	
Cancellations	(208,151)	0.55-13.75	
Outstanding at March 31, 2012	392,587	\$ 0.27-13.75	8.40 years

As of March 31, 2012, the unrecognized compensation costs related to options vesting of \$248,550 will be recognized over a period of approximately 2.25 years.

Information related to the stock options outstanding as of March 31, 2012 is as follows:

Range of Exercise Prices	Number of Shares	Weighted-Average		Exercisable Number of Shares	Exercisable Weighted-Average Exercise Price
		Remaining Contractual Life (years)	Weighted-Average Exercise Price		
\$ 1.20	207,800	9.93	\$ 1.20	27,800	\$ 1.20
\$0.55	51,000	9.87	0.55	-	0.55
\$0.27	40,000	9.29	0.27	13,334	0.27
\$1.35	1,200	7.65	1.35	1,200	1.35
\$1.25	1,200	6.66	1.25	1,200	1.25
\$6.25	1,600	4.67	6.25	1,600	6.25
\$7.75	1,200	5.66	7.75	1,200	7.75
\$11.50	800	3.67	11.50	800	11.50
\$13.75	50,427	4.11	13.75	50,427	13.75
\$20.75	37,360	3.21	20.75	37,360	20.75
\$0.27-\$20.75	392,587	8.40	\$ 4.56	134,921	\$ 11.15

The aggregate intrinsic value of the Company's "in-the-money" outstanding and exercisable options as of March 31, 2012 was \$52,150 and \$9,734, respectively.

##### 5. RESTRICTED STOCK

On December 3, 2010, Richard Forkey, who at the time of the agreement served as the Company's Chief Executive Officer, agreed to reduce his annual salary to \$100,000 per year, none of which would be deferred, and reduce his vacation accrual by \$43,011, at his new rate of pay, to \$10,000. He also entered into an agreement on December 3, 2010, as amended on October 14, 2011, to convert all \$474,646 of his previously deferred salary into 172,599 shares of the Company's common stock. One-eighth of the shares vested on January 1, 2012, and one-eighth will vest on the first day of each quarter thereafter, commencing on April 1, 2012, until the shares are fully vested.

On December 3, 2010, Joseph Forkey, who at the time of the agreement served as the Company's Chief Scientific Officer and currently serves as the Company's Chief Executive Officer, agreed to reduce his vacation accrual by \$4,824, at his current rate of pay, to \$10,000. Joseph Forkey's salary will remain the same at \$120,000 and none of it will be deferred. He also entered into an agreement on December 3, 2010, as amended on October 14, 2011, to convert all \$29,999 of his previously deferred salary into 10,909 shares of the Company's common stock. One-eighth of the shares vested on January 1, 2012, and one-eighth will vest on the first day of each quarter thereafter, commencing on



April 1, 2012, until the shares are fully vested.

On December 3, 2010, the Company agreed with Joel Pitlor, one of the Company's directors, to terminate his consulting agreement with the Company. The Company also agreed on December 3, 2010, as amended on October 14, 2011, to convert all \$170,000 of the previously deferred consulting compensation owed to Mr. Pitlor into 61,818 shares of the Company's common stock. One-eighth of the shares vested on January 1, 2012, and one-eighth will vest on the first day of each quarter thereafter, commencing on April 1, 2012, until the shares are fully vested. Mr. Pitlor will remain as a director of the Company.

The shares referenced above totaling 245,326 shares of the Company's common stock were issued in October 2011 pursuant to the Company's 2011 Deferred Compensation Plan. The shares were registered under the Company's registration statement on Form S-8 filed October 14, 2011.

The following table indicates the effects on the Company's March 31, 2012 consolidated balance sheet based upon the issuance of restricted stock in settlement of liabilities for deferred compensation and professional services in October 2011, as indicated above:

	Increase (Decrease)
Accrued Employee Compensation	\$ (504,645 )
Accounts Payable	\$ (170,000 )
Total Current Liabilities	\$ (674,645 )
Total Stockholders' Equity (Deficit)	\$ 674,645

6. SALE OF ASSETS

During the nine months ended March 31, 2012 and 2011, respectively, the Company sold equipment that was previously written off for proceeds totaling \$9,457 and \$32,883, respectively, and recorded a gain of \$9,457 and \$32,883, respectively, which is included within operating expenses in the accompanying consolidated statements of operations.

7. SALE OF PATENTS

On July 28, 2011, the Company entered into an asset purchase agreement with Intuitive Surgical Operations, Inc. ("Intuitive Surgical"), in which it received gross proceeds of \$2,500,000 (less transaction expenses of \$36,829) in connection with the sale of certain intellectual property. Pursuant to the agreement, the Company agreed to assign to Intuitive Surgical all of its currently issued and non-expired patents and pending patent applications, and Intuitive Surgical agreed to grant back to the Company a royalty-free, worldwide license to the patents in all fields outside of medical robotics, except in certain exceptional circumstances.

In connection with this agreement, the Company recorded a gain on the sale of such intellectual property of \$2,276,286 in the quarter ended September 30, 2011.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and our audited consolidated financial statements for the year ended June 30, 2011 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 28, 2011.*

*This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words "expects," "anticipates," "suggests," "believes," "intends," "estimates," "plans," "projects," "continue," "ongoing," "potential," "expect," "predict," "believe," "intend," "may," "will," "should," "could," "would" and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in this report, the risks described in our Annual Report on Form 10-K for the year ended June 30, 2011 and other reports we file with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.*

### **Overview**

We have been a developer and manufacturer of advanced optical instruments since 1982. We design and produce high-quality micro-optics, medical instruments and other advanced optical systems. Our medical instrumentation line includes laparoscopes, arthroscopes and endocouplers and a world-class product line of 3-D endoscopes for use in minimally invasive surgical procedures.

We are currently developing specialty instruments incorporating our patented Lenslock™ technology that ensures lower cost, easier reparability and enhanced durability as compared to other design approaches used in the industry. We are also aggressively pursuing the development of ultra-small instruments, some with lenses less than 1 mm in diameter, utilizing our patented microprecision™ lens technology. By combining our microprecision™ lens technology with recently introduced micro complementary metal–oxide–semiconductor, or CMOS, image sensors, we are now able to produce single-use, micro-medical cameras with diameters of approximately one millimeter.

We are registered to the ISO 9001:2008 and ISO 13485:2003 and Canadian Medical Devices Conformity Assessment System, or CMDCAS, Quality Standards and comply with the FDA Good Manufacturing Practices and the European

Union Medical Device Directive for CE marking of our medical products. Our internet website is [www.poci.com](http://www.poci.com). Information on our website is not intended to be integrated into this report.

The areas in which we do business are highly competitive and include both foreign and domestic competitors. Many of our competitors are larger and have substantially greater resources than we do. Furthermore, other domestic or foreign companies, some with greater financial resources than we have, may seek to produce products or services that compete with ours. We routinely outsource specialized production efforts as required to obtain the most cost effective production. Over the years, we have achieved extensive experience with other optical specialists worldwide.

Since the 1990s, we have maintained a Hong Kong subsidiary to support business and quality control activities as required throughout Asia. We believe the cost savings from such production are essential to our ability to compete on a price basis in the medical products area in particular and to our profitability in general.

We believe that competition for sales of our medical products and services, which have been principally sold to original equipment manufacturer, or OEM, customers, is based on performance and other technical features, as well as other factors, such as scheduling and reliability, in addition to competitive price.

We believe our future success depends to a large degree on our ability to continue to conceive and to develop new optical products and services to enhance the performance characteristics and methods of manufacture of existing products. Accordingly, we expect to continue to seek to obtain product-related design and development contracts with customers and to selectively invest our own funds on research and development.

**Critical Accounting Policies and Estimates*****General***

This management's discussion and analysis of financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, referred to as U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended June 30, 2011, filed September 28, 2011.

**Results of Operations**

Our total revenues for the quarter ended March 31, 2012, the third quarter of our fiscal year 2012, were \$382,264, as compared to \$495,423 for the same period in the prior year, a decrease of \$113,159, or 22.8%. The decrease in revenues for the quarter ended March 31, 2012 was primarily due to lower unit volume sales of micro optics and lower unit volume sales of the advanced surgical visualization system used in spinal surgery, partially offset by higher sales of endoscopes. Our total revenues for the nine months ended March 31, 2012 were \$1,380,787, as compared to \$1,615,096 for the same period in the prior year, a decrease of \$234,309, or 14.5%. The decrease in revenues for the nine month period was primarily due to lower unit volume sales of micro optics and lower unit volume sales of the advanced surgical visualization system used in spinal surgery, partially offset by higher sales of endoscopes.

Revenues from our largest customers, as a percentage of our total revenues, for the nine months ended March 31, 2012 and 2011, were as follows:

	2012	2011
Customer A	36%	20%
Customer B	15	26
Customer C	11	2

Customer D	3	20
All Others	35	32
	100%	100%

No other customer accounted for more than 10% of our revenues during those periods.

Gross profit for the quarter ended March 31, 2012 was \$10,323, as compared to \$134,406 for the same period in the prior year, which reflects a decrease of \$124,083. Gross profit for the quarter ended March 31, 2012 as a percentage of our revenues was 2.7%, a decrease from the gross profit percentage of 27.1% for the same period in the prior year. The decrease in our gross profit percentage was due primarily to lower overall unit sales volume in the quarter ended March 31, 2012 compared to the same period in the prior year. Gross profit for the nine months ended March 31, 2012 was \$260,937, as compared to \$579,433 for the same period in the prior year, which reflects a decrease of \$318,496. Gross profit for the nine months ended March 31, 2012 as a percentage of our revenues was 18.9%, a decrease from the gross profit percentage of 35.9% for the same period in the prior year. The decrease in our gross profit percentage was primarily due to lower overall unit sales volume and less favorable product mix in the nine months ended March 31, 2012 compared to the same period in the prior year. Our quarterly gross profit and gross profit percentage depend on a number of factors, including overall sales volume and mix of products sold among others, and therefore vary from quarter to quarter.

Research and development expenses were \$198,608 for the quarter ended March 31, 2011, compared to \$163,672 for the same period in the prior year, an increase of \$34,936, or 21.3%. The increase in the quarter ended March 31, 2012 compared to same period in the prior year was primarily due to lower labor and materials costs incurred on product development activities, which more than offset the decreased reimbursements we received from customers for such activities. Quarterly research and development expenses depend on our assessment of new product opportunities and available resources. Research and development expenses were net of reimbursement of related costs of \$11,822 and \$70,541 during the quarters ended March 31, 2012 and 2011, respectively. Research and development expenses were \$498,842 for the nine months ended March 31, 2012, compared to \$637,259 for the same period in the prior year, a decrease of \$138,417, or 21.7%. The decrease in the nine month period ended March 31, 2012 compared to the same period in the prior year was primarily due to lower labor and materials costs incurred on product development activities, partially offset by decreased reimbursements received from customers for such activities. Research and development expenses were net of reimbursement of related costs of \$49,252 and \$178,345 during the nine months ended March 31, 2012 and 2011, respectively.

Selling, general and administrative expenses were \$309,913 for the quarter ended March 31, 2012, compared to \$264,493 for the same period in the prior year, an increase of \$45,420, or 17.2%. The increase in the quarter ended March 31, 2012 compared to the same period in the prior year was primarily due to higher noncash stock compensation expenses related to stock options issued in the quarter ended March 31, 2012. Selling, general and administrative expenses were \$837,987 for the nine months ended March 31, 2012, compared to \$724,923 for the same period in the prior year, an increase of \$113,064, or 15.6%. The increase in the nine month period ended March 31, 2012 compared to the same period in the prior year was primarily due to a reduction in the accrued vacation liabilities for certain officers in connection with the settlement of deferred compensation liabilities recorded in the quarter ended December 31, 2010 and higher noncash stock compensation expenses primarily recorded in the quarter ended March 31, 2012.

No income tax provision was recorded in the third quarter or first nine months of fiscal years 2012 or 2011 because of the availability of loss carryforwards to offset any anticipated taxable income in fiscal year 2012 and fiscal year 2011.

#### Liquidity and Capital Resources

In July 2011, we received \$2,500,000 (less \$36,829 in transaction expenses) in connection with an asset purchase agreement with Intuitive Surgical Operations, Inc. We had immediate use of the net proceeds of \$2,463,171. This influx of capital allowed us to retire outstanding long term debt as necessary, and to satisfy our immediate cash requirements as we move forward with our business objectives to increase sales of newly developed products.

On December 15, 2011, we repaid Special Situations Fund III QP, L.P. a principal repayment of \$275,000 and accrued interest of \$95,486, for a total payment of \$370,486. On December 15, 2011, we repaid Special Situations Private Equity Fund, L.P. a principal repayment of \$275,000 and accrued interest of \$95,486, for a total payment of \$370,486. The Notes held by Special Situations Fund III QP, L.P. and Special Situations Private Equity Fund, L.P. have been satisfied in full and the obligations thereunder have been terminated. On March 31, 2012, the remaining Investor, Arnold Schumsky, further amended his remaining Note to extend the "Stated Maturity Date" of the principal to July 31, 2012 and to modify the Note such that all accrued and unpaid interest on the Note up to and including March 31, 2012 shall be due on or before April 13, 2012, on the condition that we issue to him a warrant for 5,000 shares of common stock with an exercise price of \$1.20 per share and a term of three years. On April 13, 2012, we repaid Mr. Schumsky a payment of the accrued interest of \$18,819, and such payment included all accrued and unpaid interest on the Note up to and including March 31, 2012. On May 8, 2012, we issued Mr. Schumsky the warrant according to the terms described in the amended Note.

Moving forward, we intend to build upon recent successes in technology development and new product introductions. We believe the following technology areas continue to represent significant opportunities for future sales growth:

Lenslock™ endoscopes and other minimally invasive surgical devices which provide significant benefits to surgeons and hospitals through better image quality and reduced lifetime ownership costs;  
Microprecision™ optical elements and assemblies with sizes less than 1 mm that enable the introduction of imaging capabilities in locations in the body previously inaccessible. We believe the combination of our microprecision™ lens technology with recently introduced micro CMOS image sensors will make possible the fabrication of micro-medical cameras in high volume quantities for single-use applications; and  
next generation handheld stereoendoscopes that provide high definition 3D images for use in minimally invasive surgery.

We compete in a highly technical, very competitive and, in most cases, price driven segment of the medical instrument marketplace where products can take years to develop and introduce to distributors and end users. Furthermore, research and development, manufacturing, marketing and distribution activities are strictly regulated by the U.S. Food and Drug Administration, International Organization for Standardization, and other regulatory bodies that, while intended to enhance the ultimate quality and functionality of products produced, can contribute to the significant cost and time needed to maintain existing products and develop and introduce product enhancements and new product innovations.

We have traditionally funded working capital needs through product sales, management of working capital components of our business, and by cash received from public and private offerings of our common stock, warrants to purchase shares of our common stock and convertible notes. In July 2011, we received proceeds of \$2,500,000 in connection with the execution of an asset purchase agreement with Intuitive Surgical Operations, Inc. We have incurred quarter to quarter operating losses during our efforts to develop current products including endoscopes, image couplers, night vision and micro-optic lenses, prisms and assemblies for various applications utilizing a number of proprietary and patented technologies including Lenslock™ endoscope and microprecision™ lens technologies. Our management expects that such operating losses will continue through fiscal year 2012 and until sales increase to breakeven and profitable levels. Our management also believes that the opportunities represented by these products have the potential to generate sales increases to achieve breakeven and profitable results.



If these additional revenues are not achieved on a timely basis, we will be required to pursue several options to manage cash flow and raise capital, including issuing debt or equity or entering into a strategic alliance. The sale of additional equity or convertible debt securities would result in additional dilution to our stockholders, and debt financing, if available, may involve restrictive covenants that could restrict our operations or finances. Financing may not be available in amounts or on terms acceptable to us, if at all. If we cannot raise funds on acceptable terms or achieve positive cash flow, we may not be able to continue to conduct operations, develop new products, grow market share, take advantage of future opportunities or respond to competitive pressures or unanticipated requirements, any of which would negatively impact our business, operating results and financial condition.

We have sustained recurring net losses for several years. During the year ended June 30, 2011, we incurred a net loss of \$1,052,613 and used cash in operations of \$413,525. For the quarter ended March 31, 2012, we used cash in operations of \$357,815 and our operating loss for the quarter was \$490,890. As of March 31, 2012, cash and cash equivalents were \$436,219, accounts receivable were \$119,479, and current liabilities were \$625,967. Deferred officers' salaries and director consulting expenses accrued as of September 30, 2011 were settled by the issuance in October 2011 of 245,326 shares of common stock rather than by cash payments. These deferred amounts included in current liabilities at September 30, 2011 totaled \$674,645.

Contractual cash commitments for the fiscal years subsequent to March 31, 2012 are summarized as follows:

	2012	2013	Thereafter	Total
Operating Leases	\$6,038	\$---	\$	— \$6,038
Principal & Interest (1)	68,819	—		— 68,819
Totals	\$74,857	\$----	\$	— \$74,857

(1) This amount may be reduced to the extent the holder of the Senior Secured Convertible Note elects to convert the principal on the Note into our common stock.

We have contractual cash commitments related to open purchase orders for fiscal year 2012 of approximately \$215,000.

### **Trends and Uncertainties That May Affect Future Results**

During fiscal year 2010 after implementing a number of changes to reduce cash usage and increase sales and profitability, our cash flow was positive for the first time in many years. In fiscal year 2011, the major focus of our senior management was shifted to finding a long-term solution to our obligations under the 10% Senior Secured Convertible Notes (the "Notes") which initially became due just before the beginning of fiscal year 2011. While we continued to work to advance product development and sales and marketing efforts, the requirement to find a solution for the Notes while simultaneously continuing operations of our Company with limited capital resources resulted in an overall reduction in sales volume and delay of business plans. With the consummation of an asset purchase agreement with Intuitive Surgical Operations, Inc. in July 2011, we received sufficient cash to retire the Notes and to provide working capital for our Company. Moving forward, the major focus of our senior management in fiscal year 2012 is to recover the business plan. We intend to increase sales of our existing and new technologies, and to achieve profitability.

Due to the introductory stage of many of our products and the unpredictable timing of orders from customers, it is difficult to predict with certainty the detailed rate of future revenue growth. However, we expect that current discussions with existing and new potential customers could lead to increases in our revenues. To continue to support these and future discussions, we intend to continue to develop and commercialize new products and technical innovations, in particular:

- a new generation of endoscopes that incorporate patented Lenslock™ technology and associated custom products for minimally invasive surgery;
- new components and instruments utilizing our new patented microprecision™ lens technology for optical components and endoscopes under 1 mm, and in particular, the combination of our microprecision™ lens technology with micro CMOS image sensors to produce single-use, micro-medical cameras; and
- new handheld stereo endoscopes that provide high definition 3D images for use in minimally invasive surgery.

Over the past few years, we have implemented significant changes in new product and technology development by shifting the emphasis of research and development efforts from developing underlying technologies to commercializing the applications of these new technologies. These efforts have already been realized to some degree in a number of areas. Over the past two to three years, our efforts have produced revenues from our new microprecision™ lens products and new Lenslock™ endoscopes. Our research and development efforts have also resulted in the combination of our microprecision™ lens technology with recently introduced micro CMOS image sensors to create single-use, micro-medical cameras with diameters of approximately 1 millimeter, a product which we believe could address customer opportunities in numerous medical applications not possible with currently available optics instrumentation.

During the past year, we developed and began to manufacture a new stereo endoscope with high definition quality imaging and 10 mm diameter for use in general laparoscopic surgery. This next generation 3D endoscope has been evaluated by a number of medical professionals and has been received enthusiastically. We believe that with the advent of commercially available high quality flat panel 3D displays, stereo endoscopy represents an opportunity for significant sales growth for our Company.

In April 2012, we accepted an order from a customer to purchase endoscopes for a total purchase amount of \$1,032,000. Fabrication of these endoscopes will rely heavily on our microprecision™ small lens technology. The purchase order is contingent upon execution of a supply agreement to specify, among other items, the delivery schedule of the products, and demonstration that the endoscopes meet the customer's requirements. We are responsible for all testing and validation of the products.

#### **Off-Balance Sheet Transactions**

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

#### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

#### **Item 4. Controls and Procedures.**

##### *Evaluation of Disclosure Controls and Procedures*

Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our

Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures, including internal control over financial reporting, were not effective as of March 31, 2012, to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (i) is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are intended to be designed to provide reasonable assurance that such information is accumulated and communicated to our management. Based on this evaluation, our management concluded that our internal control over financial reporting was not effective as of March 31, 2012.

The following is a description of two material weaknesses in our internal control over financial reporting:

Segregation of Duties: As previously disclosed in our annual reports on Form 10-K for the fiscal years ended June 30, 2008, 2009, 2010 and 2011, our management identified a control deficiency during the 2008 fiscal year because we lacked sufficient staff to segregate accounting duties. We believe the control deficiency resulted primarily because we have the equivalent of one and one-half persons performing all accounting-related on-site duties. As a result, we did not maintain adequate segregation of duties within our critical financial reporting applications, the related modules and financial reporting processes. This control deficiency could result in a misstatement of balance sheet and income statement accounts in our interim or annual consolidated financial statements that would not be detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

To address and remediate the material weakness in internal control over financial reporting described above, beginning with the quarter ended September 30, 2008, we instituted a procedure whereby our Chief Executive Officer and other members of our Board of Directors perform a higher level review of the quarterly reports on Form 10-Q and annual reports on Form 10-K prior to filing.

We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above. As part of our assessment of internal control over financial reporting for the quarter ended March 31, 2012, our management has evaluated this additional control and has determined that it is operating effectively.

Inventory Valuation: As previously disclosed in our annual reports on Form 10-K for the fiscal years ended June 30, 2009, 2010 and 2011, we reported a material weakness with respect to the valuation of our inventories. Specifically, the amounts used to value our inventory at June 30, 2009 with respect to overhead rates and purchased items were often inconsistent with the supporting documentation, due to year-to-year changes in overhead rates and costs of purchased items that were not properly reflected in inventory valuation. Accordingly, management had determined that this control deficiency constituted a material weakness as of June 30, 2009. One audit adjustment of approximately \$58,000 to our audited financial statements as of June 30, 2011 was necessary as a result of this condition.



To address and remediate the material weakness in internal control over financial reporting described above, beginning in the quarter ended September 30, 2009 and continuing through the quarter ended March 31, 2012, we implemented procedures to improve our inventory controls and documentation surrounding inventory valuation for overhead rates, and performed procedures to ensure that the pricing of inventory items was consistent with the supporting documentation. We believe that the step outlined above strengthens our internal control over financial reporting and mitigates the material weakness described above.

We intend to continue to remediate material weaknesses and enhance our internal controls but cannot guarantee that our efforts will result in remediation of our material weaknesses or that new issues will not be exposed in this process.

***Changes in Internal Control over Financial Reporting***

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2012, which is covered by this quarterly report on Form 10-Q, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings.**

Our Company, on occasion, may be involved in legal matters arising in the ordinary course of our business. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations. We are not aware of any pending or threatened litigation against us or our officers and directors in their capacity as such that could have a material impact on our operations or finances.

### **Item 1A. Risk Factors.**

There have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2011, as filed with the Securities and Exchange Commission on September 28, 2011.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

On April 30, 2012, we issued 6,000 unregistered shares of our common stock to the designee of Orin Hirschman, as consideration for consulting services, and such shares were valued at \$6,600. The Board approved such issuance on February 9, 2012.

With respect to the issuance of securities described above, we relied on the Section 4(2) exemption from securities registration under the federal securities laws for transactions not involving any public offering. No advertising or general solicitation was employed in offering the securities. The securities were issued to an accredited investor. The securities were offered for investment purposes only and not for the purpose of resale or distribution, and the transfers thereof were appropriately restricted by us.

### **Item 3. Defaults Upon Senior Securities.**

As of March 31, 2012, we are not in default with respect to any indebtedness.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

None.

17



**Item 6. Exhibits.**

Exhibit Description

- 2.1 Asset Purchase Agreement between the Company and Optometrics Corporation, dated January 18, 2008 (included as Exhibit 2.1 to the Form 8-K filed January 25, 2008 and incorporated herein by reference).
- 3.1 Articles of Organization of Precision Optics Corporation, Inc., as amended (included as Exhibit 3.1 to the Form SB-2 filed March 16, 2007 and incorporated herein by reference).
- 3.2 Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.2 to the Form S-1 filed December 18, 2008 and incorporated herein by reference).
- 3.3 Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated November 25, 2008 and effective December 11, 2008 (included as Exhibit 3.1 to the Form 8-K filed December 11, 2008 and incorporated herein by reference).
- 4.1 Registration Rights Agreement by and among the Company and each investor named therein, dated March 17, 2000 (included as Exhibit 4.4 to the Form S-3 filed April 28, 2000 and incorporated herein by reference).
- 4.2 Registration Rights Agreement, dated June 30, 1998 by and among the Company, Special Situations Private Equity Fund, L.P. and Special Situations Technology Fund, L.P. (included as Exhibit 4.9 to the Form 10-KSB filed September 29, 1998 and incorporated herein by reference).
- 4.3 Registration Rights Agreement by and among the Company, Special Situations Cayman Fund, L.P., Special Situations Fund III, L.P., Special Situations Private Equity Fund, L.P. and Special Situations Technology Fund, L.P., dated August 5, 1999 (included as Exhibit 4.7 to the Form 10-KSB filed September 28, 1999 and incorporated herein by reference).
- 4.4 Registration Rights Agreement by and among the Company and each investor named therein, dated February 1, 2007 (included as Exhibit 4.1 to the Form 8-K filed February 2, 2007 and incorporated herein by reference).
- 4.5 Form of Warrant to Purchase Shares of Common Stock (included as Exhibit 4.2 to the Form 8-K filed February 2, 2007 and incorporated herein by reference).
- 4.6 Registration Rights Agreement by and among the Company and each investor named therein, dated June 25, 2008 (included as Exhibit 4.1 to the Form 8-K filed June 27, 2008 and incorporated herein by reference).
- 4.7 Form of Warrant to Purchase Shares of Common Stock, dated June 25, 2008 (included as Exhibit 4.2 to the Form 8-K filed June 27, 2008 and incorporated herein by reference).
- 4.8

Edgar Filing: PRECISION OPTICS Corp INC - Form 10-Q

Form of 10% Senior Secured Convertible Note, dated June 25, 2008 (included as Exhibit 4.3 to the Form 8-K filed June 27, 2008 and incorporated herein by reference).

- 10.1 Precision Optics Corporation, Inc. 1997 Incentive Plan, as amended and restated (included as Exhibit 10.1 to the Form 10-QSB filed November 13, 2003 and incorporated herein by reference).
- 10.2 Securities Purchase Agreement by and among the Company and each purchaser named therein, dated March 13, 2000 (included as Exhibit 2.1 to the Form S-3 filed April 28, 2000 and incorporated herein by reference).
- 10.3 Form of Securities Purchase Agreement between the Company and investors (included as Exhibit 10.1 to the Form 8-K filed April 19, 2006 and incorporated herein by reference).
- 10.4 Precision Optics Corporation, Inc. 2006 Equity Incentive Plan (included as Exhibit 99.1 to the Form 8-K filed December 4, 2006 and incorporated herein by reference).
- 10.5 Purchase Agreement by and among the Company and each investor named therein, dated February 1, 2007 (included as Exhibit 10.1 to the Form 8-K filed February 2, 2007 and incorporated herein by reference).
- 10.6 Form of Incentive Stock Option Certificate (included as Exhibit 10.1 to the Form 10-QSB filed February 14, 2007 and incorporated herein by reference).

- 10.7 Form of Nonstatutory Stock Option Certificate (included as Exhibit 10.2 to the Form 10-QSB filed February 14, 2007 and incorporated herein by reference).
- 10.8 Purchase Agreement by and among the Company and each investor named therein, dated June 25, 2008 (included as Exhibit 10.1 to the Form 8-K filed June 27, 2008 and incorporated herein by reference).
- 10.9 Pledge and Security Agreement by and among the Company and each investor named therein, dated June 25, 2008 (included as Exhibit 10.2 to the Form 8-K filed June 27, 2008 and incorporated herein by reference).
- 10.10 Consulting Agreement between the Company and Jack P. Dreimiller, dated August 15, 2008 (included as Exhibit 10.1 to the Form 8-K filed August 18, 2008 and incorporated herein by reference).
- 10.11 Side Letter Agreement between the Company and the investors signatory to the Purchase Agreement, dated November 25, 2008 (included as Exhibit 10.1 to the Form 8-K filed December 11, 2008 and incorporated herein by reference).
- 10.12 Side Letter Agreement between the Company and the holders signatory to the 10% Senior Secured Convertible Note, dated December 11, 2008 (included as Exhibit 10.15 to the Form S-1 filed December 18, 2008 and incorporated herein by reference).
- 10.13 Side Letter Agreement between the Company and the holders signatory to the 10% Senior Secured Convertible Note, dated April 2, 2009 (included as Exhibit 10.16 to the Form S-1/A filed April 6, 2009 and incorporated herein by reference).
- 10.14 Compensation Agreement with Richard E. Forkey, dated December 3, 2010 (filed as Exhibit 10.11 to the Form 8-K filed December 6, 2010 and incorporated herein by reference).
- 10.15 Compensation Agreement with Joseph N. Forkey, dated December 3, 2010 (filed as Exhibit 10.12 to the Form 8-K filed December 6, 2010 and incorporated herein by reference).
- 10.16 Compensation Agreement with Joel R. Pitlor, dated December 3, 2010 (filed as Exhibit 10.13 to the Form 8-K filed December 6, 2010 and incorporated herein by reference).
- 10.17 Asset Purchase Agreement between the Company and Intuitive Surgical Operations, Inc., dated July 27, 2011 (included as Exhibit 10.1 to the Form 8-K filed August 3, 2011 and incorporated herein by reference).
- 10.18 Amendment to Pledge and Security Agreement by and among the Company and each investor named therein, dated July 27, 2011 (included as Exhibit 10.2 to the Form 8-K filed August 3, 2011 and incorporated herein by reference).
- 10.19 Demand Note in the amount of \$10,000, dated July 13, 2011, issued by the Company to Dr. Joseph N. Forkey (filed as Exhibit 10.22 to the Form 10-K filed September 28, 2011, and incorporated herein by reference.)
- 10.20 Precision Optics Corporation, Inc. 2011 Equity Incentive Plan, dated October 13, 2011 (included as Exhibit 10.2 to Form S-8 filed October 14, 2011, and incorporated herein by reference.)

- 10.21 Precision Optics Corporation, Inc. 2011 Deferred Compensation Plan, dated October 13, 2011 (included as Exhibit 10.3 to Form S-8 filed October 14, 2011, and incorporated herein by reference.)
- 10.22 Side Letter Agreement to the Compensation Agreement with Richard E. Forkey, dated October 14, 2011(included as Exhibit 10.4 to the Form 8-K filed October 19, 2011 and incorporated herein by reference).
- 10.23 Side Letter Agreement to the Compensation Agreement with Joseph N. Forkey, dated October 14, 2011(included as Exhibit 10.5 to the Form 8-K filed October 19, 2011 and incorporated herein by reference).
- 10.24 Side Letter Agreement to the Compensation Agreement with Joel N. Pitlor, dated October 14, 2011(included as Exhibit 10.6 to the Form 8-K filed October 19, 2011 and incorporated herein by reference).
- 10.25 Endorsement to 10% Senior Secured Convertible Note by the Company, dated October 31, 2011, and accepted by Special Situations Private Equity Fund, L.P. (included as Exhibit 10.2 to the Form 8-K filed November 3, 2011 and incorporated herein by reference).

- 10.26 Endorsement to 10% Senior Secured Convertible Note by the Company, dated October 31, 2011, and accepted by Special Situations Fund III QP, L.P. (included as Exhibit 10.3 to the Form 8-K filed November 3, 2011 and incorporated herein by reference).
- 10.27 Endorsement to 10% Senior Secured Convertible Note by the Company, dated March 31, 2012, and accepted by Arnold Schumsky (filed herewith).
- 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
- 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
- 32.1 Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
- 101.INS XBRL Instance Document (filed herewith).
- 101.SCH XBRL Taxonomy Extension Schema (filed herewith).
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase (filed herewith).
- 101.DEF XBRL Taxonomy Extension Definition Linkbase (filed herewith).
- 101.LAB XBRL Taxonomy Extension Label Linkbase (filed herewith).
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase (filed herewith).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRECISION OPTICS CORPORATION, INC.

Date: May 15, 2012 By: /s/ Joseph N. Forkey  
Joseph N. Forkey  
Chief Executive Officer

(Principal Executive Officer)

Date: May 15, 2012 By: /s/ Jack P. Dreimiller  
Jack P. Dreimiller  
Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)